To determine potential relationships of clinical response to tebotelimab (exploratory endpoint), IHC analyses of tumor tissue were performed to evaluate PD-L1 (a universally employed IHC biomarker for PD-1-targeted therapies) and LAG-3 expression. Here, LAG3 is linked to neoplasm.